Channel Medsystems Announces Grant Support for an Investigator-Sponsored Clinical Study Evaluating Cerene® Cryotherapy for Women With Adenomyosis

Résumé détaillé

BERKELEY, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held medical technology company dedicated to raising the standard of care for women with…

BERKELEY, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held medical technology company dedicated to raising the standard of care for women with heavy menstrual bleeding and dysmenorrhea, announced today grant support for an investigator-sponsored study (ISS) at NYU Langone Health’s Center for Fibroid Care evaluating the Cerene® Cryotherapy Device in women with MRI-confirmed adenomyosis.

The study, under the independent direction of Principal Investigator Taraneh Shirazian, M.D., Director of the Center for Fibroid Care at NYU Langone Health, has enrolled its first patients, marking an important milestone and alignment with Channel Medsystems’ scientific and clinical initiatives. The investment to support investigator-sponsored research is part of the company’s broader clinical strategy and is bolstered by its ongoing Series C financing, which recently reached a $30 million milestone.

Adenomyosis is a gynecologic condition characterized by the presence of endometrial-like tissue within the muscular wall of the uterus. The condition can be associated with severe issues for women who are suffering - including heavy menstrual bleeding, painful periods, pelvic pain and other debilitating symptoms that can significantly affect quality of life.

The Evaluation of Endometrial Cryoablation (Cerene) for the Treatment of Bleeding and Pelvic Pain in Women with Adenomyosis is a prospective, single-arm observational study designed to evaluate the effectiveness of endometrial cryoablation using the Cerene device in improving abnormal uterine bleeding, dysmenorrhea and pelvic pain in women with adenomyosis. Secondary objectives include assessing patient-reported menstrual experience, patient satisfaction and quality of life following treatment.

The study is expected to enroll up to 70 patients and will follow participants for 12-months post-treatment, with assessments conducted at baseline and at 3, 6 and 12-months.

“Adenomyosis is a debilitating…

Taraneh…

Début de l'article, extrait de Markets Insider (Business Insider). Pour lire la suite, ouvrez l'article chez le média.